• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Working Procedures for Medical Device Quality Spot Inspections in China

Working Procedures for Medical Device Quality Spot Inspections in China

Friday, 23 April 2021 / Published in Medical Device, News, NMPA Registration in China

Working Procedures for Medical Device Quality Spot Inspections in China

On April 13, the NMPA (National Medical Products Administration) published (No.46-2021) the working procedures for medical device quality spot inspections in China.

In accordance with the NMPA’s administrative measures (No.9-2020) for sampling inspection on medical devices, the working procedures consists of 20 pages addressing the details for the following items whilst 29 pages are appendices.

  • Development of the quality spot inspection plan by the China government
  • Role and responsibilities of the parties involved to carry out the quality spot inspections
  • Inspection work procedure
  • Re-inspection
  • Inspection report and results (Paper / Electronic Certificates)
  • Objections and appeals against inspection results
  • Compilation of the inspection results into quality analysis reports
  • Follow up work for failed inspections and using inspection reports as statutory evidence for administrative penalties

The announcement focuses on the standard working procedure of quality spot inspection to identify the possible risks of product safety. The inspection takes place in China, but it may occur to both domestic and overseas medical devices. The submission of quality analysis report will be required if necessary whilst post-market activities will also be involved.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Inspection, Product Quality Spot Inspections

What you can read next

NMPA Major Updates Concerning Software as Medical Device (SaMD)
china-vaccine-production
China vaccine production and distribution rules released
China drug registration evaluation
China drug registration evaluation report 2021 released

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP